| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 6,829 | 8,507 | 10,390 | 8,164 |
| Cost of goods sold | 1,596 | 1,519 | 1,497 | 1,928 |
| Gross profit | 5,233 | 6,988 | 8,893 | 6,236 |
| Research and development | 5,316 | 6,269 | 5,903 | 5,316 |
| Sales and marketing | 3,936 | 5,786 | 5,698 | 6,207 |
| General and administrative | 6,028 | 8,080 | 8,526 | 7,745 |
| Restructuring expense | 3,058 | - | - | - |
| Depreciation and amortization | 1,044 | 1,080 | 1,061 | 1,021 |
| Total operating expenses | 19,382 | 21,215 | 21,188 | 20,289 |
| Operating loss | -14,149 | -14,227 | -12,295 | -14,053 |
| Interest income | 1,733 | 1,870 | 2,034 | 2,496 |
| Total other income | 1,733 | 1,870 | 2,034 | 2,496 |
| Loss before income taxes | -12,416 | -12,357 | -10,261 | -11,557 |
| Net loss | -12,416 | -12,357 | -10,261 | -11,557 |
| Earnings per share, basic | -0.12 | -0.12 | -0.1 | -0.11 |
| Earnings per share, diluted | -0.12 | -0.12 | - | -0.11 |
| Weighted average number of shares outstanding, basic | 106,613,075 | 106,403,540 | 105,950,480 | 105,109,603 |
| Weighted average number of shares outstanding, diluted | 106,613,075 | 106,403,540 | 105,950,480 | 105,109,603 |
MAXCYTE, INC. (MXCT)
MAXCYTE, INC. (MXCT)